Диссертация (1140119), страница 25
Текст из файла (страница 25)
Siris S.G. Assessment and treatment of depression in schizophrenia. //Psychiatr Ann. 1994. – Vol.24. – P.463-467.172. Siris S.G. Depression in schizophrenia: perspective in the era of "atypical"antipsychotic agents. // Am J Psychiatry. 2000. – Vol.157. – P.1379-1389.173. Siever L.J., Davis K.L. Pathophysiology of schizophrenic disorders:perspectives from the spectrum //Am. J. Psychiat. 2004. - Vol.161. - 3. – P.398-413.174. Siris SG, Bench C (2003) Depression and schizophrenia.
In: HirschSR,Weinberger DR. // Schizophrenia. Oxford, Blackwell Publishing, P.142–167175. Skodol AE, Grilo GM, Keyes K, Geier T. Relationship of PersonalityDisorders to the Course of Major Depressive Disorder in a Nationally RepresentativeSample. // Am J Psychiatry. 2011. – Vol.168(3). – P.257–264.176. Skodol AE, Bender DS, Morey LC, Clark LA, Oldham JM, Alarcon RD, etal. Personality disorder types proposed for DSM-5. // J Pers Disord. 2011. – Vol.25(2).– P.136-169.133177. Skodol AE, Gunderson J.G., McGlashan T.H., Dyck I.R.
et al. Functionalimpairment in patients with schizotypal, borderline, avoidant, or obsessive-compulsivepersonality disorder. // Am J Psychiatry 2002; 159:276–283178. Soloff PH, George A, Nathan RS, Schulz PM, Ulrich RF, Perel JM. Progressin pharmacotherapy of borderline disorders: A double-blind study of amimptyline,haloperidol, and placebo, // Arch. Gen. Psychiatry.
1986. – Vol.43. – P.691-697.179. Soloff PH. George A, Nathan S ct a/. Amimptylme versus haloperidol inborderlines: Final outcomes and predictors of response. // J. Clin. Psychopharmacol.1989. – Vol.9. – P.238-246.180. Soloff PH. Cornelius J. George A, Nathan S, Perel JM, Ulrich RF. Eficacyof phenelzine and haloperidol in borderline personality disorder. // Arch. Gen. Psychiatry.1993. – Vol.50.
– P.377-385.181. Tandon R., Nasrallah H.A., Keshavan M.S. Shizophrenia, "just the facts". 4.Clinical feature and conceptualization. // Schizophr Res. 2009. – Vol.110. – P.1-23.182. Tapp A., Kilzieh N., Wood A.E. et al. Depression in patients withschizophrenia during an acute psychotic episode // Compr. Psychiatry. 2001. - Vol.42(4).- P. 14–318.183. Tiihonen J, Suokas JT, Suvisaari JM, et al.
Polypharmacy withantipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. //Arch Gen Psychiatry 2012. – Vol.69. – P.476-483.184. Tissot R. et al. Long-term drug therapy in psychosis //Long-Term Treatmentof Psychotic States. Long-term drug therapy in psychotic states. NY. – 1977.
– С. 89-111.185. Tonna M, De Panfilis C, Marchesi C. Mood-congruent and mood-incongruent psychotic symptoms in major depression: The role of severity andpersonality. // J Affect Disord. 2012 Vol.141(2-3). – P.464-468.186. Tonna M., De Panfilis C., Provini C., Marches, C., The effect of severity andpersonality on the psychotic presentation of major depression. // Psychiatry Research.2011.
– Vol.190. – P.98–102.134187. Tollefson GD, Sanger TM, Beasley CM, Tran PV. A Double-Blind,Controlled Comparison of the Novel Antipsychotic Olanzapine versus Haloperidol orPlacebo on Anxious and Depressive Symptoms Accompanying Schizophrenia. BiolPsychiatry. 1998. – Vol.43(11). – P.803–810.188. Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN,Graffeo KA, Thieme ME (1997) Olanzapine versus haloperidol in the treatment ofschizophrenia and schizoaffective and schizophreniform disorders: results of aninternational collaborative trial. // Am J Psychiatry. – Vol.154.
– P.457–465.189. Tollefson GD, Sanger TM, Lu Y, Thieme ME. Depressive signs andsymptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol.//Arch Gen Psychiatry. 1998. – Vol.55. – P.250–258.190. Thompson J., Berk M., Dean O. et al. Who’s left? Symptoms ofschizophrenia that predict clinical trial dropout // Hum. Psychopharmacol. 2011. Vol.26. - P 609–613.191.
Torgersen S., Kringlen E., Cramer V. The prevalence of personalitydisorders in a community sample. // Archives of General Psychiatry. 2001. – Vol.58. –P.590-596192. Trivedi MH. Treatment-resistant depression: new therapies on the horizon.Ann Clin Psychiat 2003; 1: 59–70.193. Tsuang M. T., Stone W. S., Faraone S. V. Schizoaffective and schizotypaldisorders. // New Oxford Textbook of Psychiatry. 2000.
– Vol.1. – P.636-644.194. Van Putten T., May P. R. A. 'Akinetic depression'in schizophrenia //Archivesof General Psychiatry. – 1978. – Т. 35. – №. 9. – С. 1101-1107195. Voglmaier M.M., Seidman L.J., Salisbury D.F. et al. Deficit in verballearning in schizotypal personality disorder. // Biol Psychiatry. 1994. – Vol.35(9). –P.741.196. Voglmaier M, Seidman L, Salisbury D, McCarley R. Neuropsychologicaldysfunction in schizotypal personality disorder: a profile analysis.
Biol Psychiatry.1997.– Vol.41. – P.530–540.135197. Voruganti L., Awad A.G. Neuroleptic Dysphoria: Towards a New Synthesis.// Psychopharmacology (Berl), 2004. – Vol.171(2),. – P.121–132.198. Weissman MM соавт A comparison of three scales for assessinf socialfunctioning in primary care // Am. J/ Psychiatry/ 2001/ Vol 20 P460-466199. Whitehead C., Moss S., Cardno A., Lewis G. Antidepressants for thetreatment of depression in people with schizophrenia: a systematic review. Psychol Med2003; 33: 4: 589-599.200. Wijkstra J., Lijmer J., Burger H., Geddes J., Nolen W.A.
Pharmacologicaltreatment for psychotic depression // Cochrane Database Syst. Rev. - 2013. - 11. CD004044.201. Wood K., Harris M.J., Morreale A., Rizos A.L. Drug induced psychosis anddepression in the elderly. - Psychiatr. Clin. North. Am. 1988; 11: 167-193.202. Wykes Т., Hauward P., Thomas N. et al. What are the effects of groupcognitive behaviour therapy for voices? A randomized control trial // Schizophr. Bull.2005. Vol. 77.
P. 201–210.203. Zicook S., McAdams L.A., Kuck J. et al. Depressive symptoms inschizophrenia. // Am J Psychiatry. 1999. – Vol.156(11). – P.1736-1743.204. Zimmerman M., Coryell W. DSM-III personality disorder diagnoses in anonpatient sample. // Arch. Gen. Psychiatry. 1989. – Vol.46. – P.682-689.205. Zimmerman M., Pfohl B., Coryell W.H., Stangl, D., Corenthal, C.
(1988)Diagnosing personality disorder in depressed patients. // Arch. Gen. Psychiatry. 1988. Vol.45. – P.733-737.206. Zimmerman M., Pfohl, B. Coryell, W.H., Corenthal C., Stangl D. Majordepression and personality disorder. // J. Affect. Disord. 1999. – Vol.22. – Vol.199-210.207.
Zisook S, Kasckow JW, Lanouette NM, et al. Augmentation with citalopramfor suicidal ideation in middle-aged and older outpatients with schizophrenia andschizoaffective disorder who have subthreshold depressive symptoms: a randomizedcontrolled trial.
J Clin Psychiatry 2010. – Vol.71. – P.915-922.136СПИСОК ИСПОЛЬЗОВАННЫХ СОКРАЩЕНИЙАД – антидепрессантИМАО – ингибиторы моноаминооксидазыИОЗСиН – ингибиторы обратного захвата серотонина и норадреналинаКТ – компьютерная томографияМКБ-10 – Международная классификация болезней 10-го пересмотраМРТ – магнитно-резонансная томографияПАВ – психоактивные веществаСИОЗС – селективные ингибиторы обратного захвата серотонина ЧМТ – черепно-мозговая травмаЭКГ – электрокардиография (электрокардиограмма)ЭЭГ – электроэнцефалография (электроэнцефалограмма)CGI (Clinical Global Impression Scale) – шкала общего клинического впечатленияCGI-I (Clinical Global Impression Scale – Improvement) – субшкала улучшениясостояния шкалы общего клинического впечатленияCGI-S (Clinical Global Impression Scale – Severity) – субшкала тяжести состоянияшкалы общего клинического впечатленияDSM-V (The Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition) –Руководство по диагностике и статистике психических расстройств 5-гопересмотра137CDSS (Calgary Depression Scale for schizophrenia) – шкала депрессии Калгари убольных шизофрениейYMRS (Young Mania Rating Scale) - Шкала мании Янга.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
